Genizon BioSciences reported a license and collaboration agreement with Pfizer for diagnostic rights to Genizon’s discovery programs in Alzheimer’s disease, attention deficit hyperactivity disorder, and endometriosis. Genizon retains therapeutic rights.
Under the terms of the agreement, Pfizer will pay Genizon upfront license fees and funding for research on genetic variations associated with the diseases. Pfizer will also purchase an equity stake in Genizon.
The collaboration involves discovery of diagnostic markers from three ongoing genome-wide association studies of the Quebec Founder Population using Genizon’s technology platform. The unique genetic heritage of the Quebec Founder Population facilitates discovery of genetic markers that are predictive of disease susceptibility, according to the company.
The collaboration will expand these discoveries by including results with those from genome wide association studies from general populations.